Literature DB >> 11712771

Electronic prescribing via the internet for a coronary artery disease and hypertension megatrial.

R Cooper-DeHoff1, E Handberg, C Heissenberg, K Johnson.   

Abstract

A unique feature of the International Verapamil SR/Trandolapril Study (INVEST) is the Internet-based, electronic data capture system developed at the University of Florida for this trial. This system allows for direct collection of patient enrollment data, randomization, study drug prescribing, and real-time monitoring of patient data online. In this trial, immediate transmission of patient-specific data occurs using online data collection forms. Investigators only need a personal computer with access to the Internet: no complicated hardware, software systems, or paper storage files are necessary. INVEST is the first large randomized clinical trial to use electronic prescribing systems in the research setting. Electronic prescribing eliminates errors associated with illegible handwriting, inappropriate dosing, and inappropriate medication choice. Because the INVEST protocol allows flexibility of medication choice and dosage range within randomly assigned treatment strategies based on patient tolerance and blood pressure response, physician investigators may use individual practice patterns and preferences. The electronic system provides guidance to physicians relative to the addition of medication or dosage adjustments within the protocol. Electronic tracking and reporting mechanisms have enabled investigators in this complex megatrial to enroll, randomize, and manage patients in real time with great accuracy.

Entities:  

Mesh:

Year:  2001        PMID: 11712771      PMCID: PMC6654999          DOI: 10.1002/clc.4960241706

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  4 in total

1.  INVEST revisited: review of findings from the International Verapamil SR-Trandolapril Study.

Authors:  Rhonda M Cooper-DeHoff; Eileen M Handberg; Giuseppe Mancia; Qian Zhou; Annette Champion; Udo F Legler; Carl J Pepine
Journal:  Expert Rev Cardiovasc Ther       Date:  2009-11

2.  Factors influencing blood pressure response to trandolapril add-on therapy in patients taking verapamil SR (from the International Verapamil SR/Trandolapril [INVEST] Study).

Authors:  Martin Brunner; Rhonda M Cooper-DeHoff; Yan Gong; Jason H Karnes; Taimour Y Langaee; Carl J Pepine; Julie A Johnson
Journal:  Am J Cardiol       Date:  2007-04-16       Impact factor: 2.778

3.  Genetic Variants Associated With Uncontrolled Blood Pressure on Thiazide Diuretic/β-Blocker Combination Therapy in the PEAR (Pharmacogenomic Evaluation of Antihypertensive Responses) and INVEST (International Verapamil-SR Trandolapril Study) Trials.

Authors:  Oyunbileg Magvanjav; Yan Gong; Caitrin W McDonough; Arlene B Chapman; Stephen T Turner; John G Gums; Kent R Bailey; Eric Boerwinkle; Amber L Beitelshees; Toshihiro Tanaka; Michiaki Kubo; Carl J Pepine; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  J Am Heart Assoc       Date:  2017-11-02       Impact factor: 5.501

4.  A drug dose model for predicting clinical outcomes in hypertensive coronary disease patients.

Authors:  William J Elliott; Ann C Hewkin; Stuart Kupfer; Rhonda Cooper-DeHoff; Carl J Pepine
Journal:  J Clin Hypertens (Greenwich)       Date:  2005-11       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.